✦ LIBER ✦

The role of prostate-specific antigen as part of the diagnostic triad and as a guide when to perform a biopsy

✍ Scribed by R. Joseph Babaian; Joseph L. Camps

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 385 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19911101)68:9<2060::aid-cncr2820680936>3.0.co;2-i

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiotherapy for localized prostate carc

Radiotherapy for localized prostate carcinoma : The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen

✍ Juanita M. Crook; Yasir A. Bahadur; R. Gregory Bociek; Gad A. Perry; Susan J. Ro 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru

Receiver-operating characteristic as a t

Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms—What has to be considered?

✍ Klaus Jung; Carsten Stephan; Michael Lein; Brigitte Brux; Pranav Sinha; Dietmar 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

Probability of prostate cancer as a func

Probability of prostate cancer as a function of the percentage of free prostate-specific antigen in patients with a non-suspicious rectal examination and total prostate-specific antigen of 4–10

✍ L. Martínez-Piñeiro; J. M. García Mediero; P. González Gancedo; A. Tabernero; D. 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 337 KB

Can prostate-specific antigen be used as

Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer?

✍ B. Seckin; C. T. Anthony; B. Murphy; M. S. Steiner 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 444 KB

It is current practice in many clinical trials evaluating new chemotherapy regimens for the treatment of advanced prostate cancer to use prostate-specific antigen (PSA) decline as a response criteria with the assumption that the level of PSA reflects the efficacy of chemotherapy. Advanced prostate c

The ratio of prostate-specific antigen (

The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL

✍ Carsten Stephan; Greta Stroebel; Marc Heinau; Andre Lenz; Andreas Roemer; Michae 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 236 KB

## Abstract ## BACKGROUND The objective of this study was to evaluate the prostate specific antigen (PSA) density (PSAD) (the quotient of PSA and prostate volume) compared with the percent free PSA (%fPSA) in different total PSA (tPSA) ranges from 2 ng/mL to 20 ng/mL. Possible cut‐off levels depen

The percentage of prostate needle biopsy

The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy : Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database

✍ Stephen J. Freedland; William J. Aronson; Martha K. Terris; Christopher J. Kane; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

## Background: The authors previously found that, although the total percentage of prostate needle biopsy cores with carcinoma was a significant predictor of prostate specific antigen (psa) failure among men undergoing radical prostatectomy (rp), there was a trend toward a lower risk of recurrence